Navigation Links
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients

ward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward- looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended March 31, 2007, which are on file with the SEC. Copies of this and other documents are available from the Company.

CONTACT: Kate Corcoran, Ph.D., Vice President, Corp. Development of IsisPharmaceuticals, Inc., +1-760-603-2331

Web site: http://www.isispharm.com/

Ticker Symbol: (NASDAQ-NMS:ISIS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/28/2015)... and PITTSBURGH , Aug. ... ) today announced that its shareholders have approved ... PRGO ; TASE) and the related issuance ... an extraordinary general meeting of shareholders held today. ... cast at the extraordinary general meeting. In addition, ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... PHIA) today announced its presence at  ESC Congress 2015 , where ... Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people ...
(Date:8/27/2015)... 27, 2015 DURECT Corporation (Nasdaq: DRRX ... at three upcoming healthcare conferences.  , ... present at the Rodman & Renshaw Investment Conference on ... conference is being held at the St. Regis Hotel ... live audio webcast of the presentation will be available ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4DURECT to Participate in Upcoming Healthcare Conferences 2
...  Digestive Care, Inc. (DCI), announced that the company ... approval of its New Drug Application (NDA) for ... Insufficiency (EPI) due to cystic fibrosis (CF) or ... unique pancreatic enzyme product containing bicarbonate-buffered enteric-coated microspheres ...
... May 18, 2012  Ocera Therapeutics Inc., a privately-held ... of proprietary agents to treat gastrointestinal and liver ... CE Mark for Zysa™ (spherical carbon adsorbent, formerly ... (IBS-d), a condition affecting 10-15% of the Western ...
Cached Medicine Technology:Digestive Care, Inc. Announces FDA Approval of PERTZYE™ (pancrelipase) Delayed-Release Capsules 2Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 2Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 3
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor ... Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an official ... , “With the help of the medical community and the University of Illinois at ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones ... personally be struggling with chemical dependency, may be able to find some hope ... results-driven holistic treatment center for addiction located in Western Michigan. Focusing on several ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... “ Frequentz ... look at the latest and coolest applications on the market for iOS, Android, and ... and shared with viewers how this software allows businesses to track product movement from ...
(Date:8/28/2015)... FL. (PRWEB) , ... August 28, 2015 , ... ... for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on ... that it should begin with the employer and employees getting together for meaningful ...
(Date:8/28/2015)... TN (PRWEB) , ... August 28, 2015 , ... ... recipients of the Veterans Award, honoring military veterans leading in business. Mr. ... honorees. , The inaugural Nashville Business Journal's 2015 Veterans Awards will ...
Breaking Medicine News(10 mins):Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2
... US researchers have discovered a non-invasive elastography technique that ... to radiation. ,The technique found by ... measuring muscle noise to reveal a patients condition. ... 16 sensors, each 1.5 centimetres apart, along the thigh ...
... Huxley has said that, "Although there was support for a ... of heart disease , the relationship is not as strong ... may have on heart disease are dwarfed by other risk ... ,Coronary heart disease is the leading cause ...
... who are hard of hearing. But the authorities have hardly ... problem has mysteriously persisted for decades in the Muslim-dominated Jhumarvad ... ,Shamshool Mia, a 62-year-old villager, said: "I am hard ... treatment failed to cure me. I will have to suffer ...
... public support for the fight against kidney diseases was kicked ... from the marathon, hosted by the New York Road Runners ... Arab Emirates (UAE), will go to the US National Kidney ... entrants from around the world, including 1000 women, 29 runners ...
... suspects in police custody is standard operating procedure for ... the idea that using a Taser could lead to ... the final results of a study conducted by emergency ... (UCSD) Medical Center showed no lasting effects of the ...
... Even before women with breast cancer undergo chemotherapy, ... activity levels, according to a new study ... in Omaha, Nebraska. ,Researchers say their ... following breast cancer surgery and before any further ...
Cached Medicine News:Health News:The Plight of Jharkhand's Mysterious deaf Village 2Health News:Healthy Humans Not Harmed By Taser 2Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 2Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 3
... new Eclipse TS-100 is an innovative ... high quality tool complements any research ... CFI60 optics offer brilliant, sharp ... superb optical performance with high resolution ...
... Nikon Instruments Inc., a world leader ... the introduction of its new Universal ... Nikon Eclipse upright microscope models, including ... This Universal Epi Illuminator provides ...
... monochrome digital CCD camera ideal for demanding low-light ... high-resolution images with outstanding clarity and detail. ... Live Image Frame Rate - ... 170x120 (8x8) Image Display Speed ...
... Sonys new DFW-SX910 digital camera is ... CCD with square pixels and offers excellent ... resolution). This camera delivers uncompressed, ... easy-to-use asynchronous electronic shutter function with an ...
Medicine Products: